News
05.11.2012 | Company News
Biogen Idec began a double-blind, placebo-controlled Phase Ib trial01.01.2012 | Company News
Neurimmune acquires USD 1.9m funding from Swiss CTI06.04.2011 | Company News
Biogen Idec submitted an investigational new drug (IND) application10.03.2011 | Company News
Neurimmune introduced BIIB03720.12.2010 | Press Release
Biogen Idec and Neurimmune announce agreement on three neurodegenerative disease programs13.04.2010 | Press Release
Neurimmune Therapeutics AG awarded the 2010 ZKB TECHNOPARK® Pioneer Award18.08.2009 | Press Release
Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development03.11.2008 | Company News
New facility at the Bio-Technopark Zurich in Schlieren20.11.2007 | Press Release
Biogen Idec and Neurimmune Therapeutics announce alliance to develop treatments for Alzheimer’s disease